The above results suggest that HucMSCs-Ex may act on more than one pathway and may promote lipid degradation, reduce lipid synthesis, or activate autophagic flux level to accelerate lipid degradation or fatty acid synthesis by regulating AMPK/mTOR signaling pathway or upregulating EI24 protein levels to achieve NASH prognosis improvement. Here, MTOR is linked to metabolic dysfunction-associated steatohepatitis.